Showing papers in "Ophthalmology in 2018"
••
TL;DR: A deep learning system can detect referable GON with high sensitivity and specificity and coexistence of high or pathologic myopia is the most common cause resulting in false-negative results.
521 citations
••
National University of Singapore1, Harvard University2, Yamagata University3, University of Toronto4, Federal University of São Paulo5, International Institute of Minnesota6, Moorfields Eye Hospital7, University of New South Wales8, Shanghai Jiao Tong University9, National Institutes of Health10, University of Melbourne11
TL;DR: The International Council of Ophthalmology Guidelines for Diabetic Eye Care 2017 summarize and offer a comprehensive guide for DR screening, referral and follow-up schedules for DR, and appropriate management of vision-threatening DR, including diabetic macular edema (DME) and proliferative DR, for countries with high- and low- or intermediate-resource settings.
381 citations
••
TL;DR: The authors' deep learning algoritm revealed a weighted κ outperforming human graders in the AREDS study and is suitable to classify AMD fundus images in other datasets using individuals >55 years of age.
353 citations
••
TL;DR: Adjudication reduces the errors in DR grading by using a small number of adjudicated consensus grades as a tuning dataset and higher-resolution images as input, and to train an improved automated algorithm for DR grading.
328 citations
••
TL;DR: The school-based outdoor promotion program effectively reduced the myopia change in both nonmyopic and myopic children, and outdoor activities with strong sunlight exposure may not be necessary for myopia prevention.
303 citations
••
TL;DR: There is a significant burden of VI from uncorrected presbyopia, with the greatest burden in rural areas of low-resource countries.
283 citations
••
TL;DR: 2 large, multicenter randomized clinical trials evaluating the safety and efficacy of anti-VEGF monotherapy and combination with photodynamic therapy (PDT) recently reported initial first-year outcomes, providing level I evidence to guide clinicians in choosing the most appropriate therapy for PCV.
250 citations
••
TL;DR: Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.
237 citations
••
TL;DR: Ranibizumab 0.5 mg administered according to a T&E regimen was statistically noninferior and clinically comparable with a monthly regimen in improving VA from baseline to the end of study.
201 citations
••
TL;DR: Half-dose PDT is superior to HSML for treating patients with chronic central serous chorioretinopathy, leading to a significantly higher proportion of patients with complete resolution of SRF and functional improvement.
183 citations
••
TL;DR: Topical rhNGF is safe and more effective than vehicle in promoting healing of moderate-to-severe NK, a rare degenerative corneal disease resulting from impairedCorneal innervation.
••
TL;DR: The basic science underlying the development of Rho kinase inhibitors as a therapy to lower IOP is described and the results of the clinical studies reported to date are summarized to summarized.
••
TL;DR: Subretinal hyperpigmentation is consistent with the survival of viable transplanted hESC-derived RPE cells, but may reflect released pigment in their absence, and intervention in early stage of disease should be approached with caution.
••
National Institute for Health Research1, University of Bristol2, University College London3, Oregon Health & Science University4, Federal University of São Paulo5, Paris Descartes University6, University of Miami7, University Hospitals Bristol NHS Foundation Trust8, Kyushu University9, Johns Hopkins University School of Medicine10, Manchester Royal Eye Hospital11
TL;DR: Consensus guidelines were developed based on published literature, expert opinion, and practical experience to bridge the gap between clinical needs and medical evidence to support the treatment of patients with noninfectious uveitis with noncorticosteroid immunomodulatory agents.
••
••
TL;DR: Reduction in best-corrected visual acuity (BCVA) was associated mainly with the development of CNV or CNV-related macular atrophy and enlargement of macularitis and main risk factors were older age, longer axial length, and development of PPA.
••
Oregon Health & Science University1, University of Barcelona2, Paris Descartes University3, Université de Montréal4, Tokyo Medical University5, Duke University6, University of Tokyo7, Rabin Medical Center8, Federal University of São Paulo9, Stanford University10, Katholieke Universiteit Leuven11, AbbVie12, Austral University13, University of Utah14, University of Tübingen15, National Institute for Health Research16
TL;DR: Patients with active Uveitis at study entry who received adalimumab therapy were likely to achieve quiescence, improve visual acuity, and reduce their daily uveitis-related systemic corticosteroid use.
••
TL;DR: Although DMEK had a significantly lower risk of immunologic rejection, rejection episodes rarely resulted in graft failure within 5 years with either procedure, and five-year graft survival was similar between DMEk and DSEK.
••
TL;DR: A novel and possibly avoidable maculopathy associated with chronic exposure to pentosan polysulfate sodium (PPS) is described despite generally intact visual acuity and subtle funduscopic findings.
••
TL;DR: In this paper, the authors investigated the relationship between macular and peripapillary vessel density and progressive retinal nerve fiber layer (RNFL) loss in patients with mild to moderate primary open-angle glaucoma.
••
TL;DR: GA enlargement, which was influenced by lesion features, was relentless, resulting in rapid central vision loss, and the genetic variants associated with faster enlargement were partially distinct from those associated with risk of incident GA.
••
TL;DR: Disease-specific, time-updated modeling of clinical data for several uveitides suggests superior prevention of ocular complications and visual outcomes with immunosuppression, and oral corticosteroids at doses low enough for safe long-term therapy are ineffective, implying that immunOSuppression should be part of the initial regimen.
••
TL;DR: The IRIS Registry can be used to answer questions about practice patterns, use, disease prevalence, clinical outcomes, and the comparative effectiveness of different treatments and is a unique, large, real-world data set that is available for analytics to provide perspectives and to learn about current ophthalmic care and treatment outcomes.
••
TL;DR: New guidelines recommend the combination of urgent brain magnetic resonance imaging with diffusion-weighted imaging, vascular imaging, and clinical assessment to identify TMVL, BRAO, and CRAO patients at highest risk for recurrent stroke, facilitating early preventive treatments to reduce the risk of subsequent stroke and cardiovascular events.
••
TL;DR: OCT-A measures detect changes in retinal microvasculature before VF damage is detectable in patients with POAG, and these changes may reflect damage to tissues relevant to the pathophysiology of glaucoma.
••
TL;DR: These results demonstrate the potency of the ablate-and-replace strategy to treat RP caused by different Rho mutations and suggest that this strategy may be used to treat a wide array of dominant diseases in ophthalmology and other fields.
••
TL;DR: OCT-A found that MvD was frequent in progressive OAG eyes on the choroidal map of OCT-A, which was more frequently found at the prior DH locations in eyes with DH, and were factors associated with progressive RNFL thinning.
••
TL;DR: Emmixustat did not reduce the growth rate of GA in AMD and the most common adverse events were ocular in nature and likely related to the drug's mechanism of action.
•
TL;DR: Rhegmatogenous retinal detachment is predominantly a disease of the population older than 50 years, and males are more susceptible to RRD, which is highly dependent on demographic characteristics.
••
TL;DR: The 10-year progression rate of myopic maculopathy in this elderly Chinese population was 35.5%, increasing from 15 of 79 eyes in category 1 of myopy maculopathic at baseline to 17 of 24 eyes with patchy chorioretinal atrophy in 2011, and the 1 eye with macular atrophy.